Bladder Cancer Coverage from Every Angle
Advertisement
Advertisement

Daniel M. Geynisman, MD, on a Strategic Approach to Neoadjuvant Treatment of Bladder Cancer

Posted: Monday, February 22, 2021

Daniel M. Geynisman, MD, of Fox Chase Cancer Center, discusses the strategy used in the RETAIN BLADDER study, in conjunction with neoadjuvant chemotherapy, to reduce the extent of eventual surgical intervention for patients with bladder cancer.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.